They performed PET studies in nude mice bearing bilateral (CXCR4+ and CXCR4−) PC3 xenograft tumours and showed excellent tumour targeting, a sevenfold improvement over existing 18F-fluorinated ligands reported to date resulting in high tumour to background ratios. The gene discussed is CXCR4; the disease is neoplasm.